These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23880474)

  • 1. Low-dose metronomic chemotherapy: a systematic literature analysis.
    Lien K; Georgsdottir S; Sivanathan L; Chan K; Emmenegger U
    Eur J Cancer; 2013 Nov; 49(16):3387-95. PubMed ID: 23880474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.
    Cramarossa G; Lee EK; Sivanathan L; Georgsdottir S; Lien K; Santos KD; Chan K; Emmenegger U
    Biomark Med; 2014; 8(6):893-911. PubMed ID: 25224945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
    J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
    Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
    Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
    Raphael J; Desautels D; Pritchard KI; Petkova E; Shah PS
    Eur J Cancer; 2018 Mar; 91():38-46. PubMed ID: 29331750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
    Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
    Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
    Otsuka H; Fujii T; Toh U; Iwakuma N; Takahashi R; Mishima M; Takenaka M; Kakuma T; Tanaka M; Shirouzu K
    Breast Cancer; 2015 Jul; 22(4):335-42. PubMed ID: 23827973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
    Emmenegger U; Francia G; Chow A; Shaked Y; Kouri A; Man S; Kerbel RS
    Neoplasia; 2011 Jan; 13(1):40-8. PubMed ID: 21245939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
    Perroud HA; Rico MJ; Alasino CM; Queralt F; Mainetti LE; Pezzotto SM; Rozados VR; Scharovsky OG
    Future Oncol; 2013 Mar; 9(3):451-62. PubMed ID: 23469980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.
    Petrelli F; Di Cosimo S; Lonati V; Barni S
    Clin Breast Cancer; 2016 Oct; 16(5):327-334. PubMed ID: 27282844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
    Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
    Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
    Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.